Exhibit 99.1

 picture2a01.jpg
 Cantel Medical Reports Financial Results for its Second Quarter Fiscal Year 2019
Medical segment continues strong double-digit growth
Net sales of $224.5M, up 5.4%, with organic sales growth of 5.3%
GAAP diluted EPS of $0.45, down 42.1%
Non-GAAP diluted EPS of $0.57, down 20.0%
GAAP net income of $18.8M, down 42.1%
Non-GAAP net income of $23.6M, down 20.5%
Little Falls, New Jersey- (February 28, 2019) - Cantel Medical Corp. (NYSE: CMD) today announced financial results for its second quarter ended January 31, 2019.
 
Jørgen B. Hansen, President and Chief Executive Officer, stated, “We are pleased to see continued strong double-digit sales growth in our Medical segment, which was partly offset by softer results in our Life Sciences and Dental businesses. We expect continued momentum in our Medical segment, and acceleration in our Dental franchise in the second half of the year while managing through a challenging environment in our Hemodialysis Water business.

Our 5.4% reported sales increase was driven by organic growth of 5.3%, the impact from acquisitions of 1.1%, and an unfavorable impact from foreign currency of 1.0%. We continue to perform well internationally where sales were up 7.3%, with 11.3% organic growth. Our US business had a solid quarter and grew 4.7%.”

Financial Highlights:
Medical sales grew 10.2%, with organic growth of 11.3%, with strong performance across all core product lines and regions. Recurring revenue for this segment was up 10.4%, and capital equipment grew 9.4%. Our Life Sciences segment decreased 0.9%, primarily due to softness in our Hemodialysis Water business and the sale of our High Purity Water business in Canada. Our Dental segment reported a year over year decline of 0.4%, including a decrease of 0.7% organically, predominantly related to the temporary effect of general inventory adjustments by our channel partners.

The prior year change in tax legislation, along with the specific investments we have made to our business have had an impact on both GAAP and Non-GAAP earnings. We estimate the impact to GAAP diluted EPS from the tax true up and investments to be a negative $0.26 per diluted share, with prior year tax rate driving $0.22 per diluted share and net investments of $0.04 per diluted share. The impact to Non-GAAP diluted EPS was a negative $0.08 per share, with prior year tax rate driving $0.04 per diluted share and net investments $0.04 per diluted share.

The Company's balance sheet remains strong with ample capacity to support the strategic plan. The second quarter ended with cash of $71.0M and gross debt of $240.0M, while generating adjusted EBITDAS of $42.4M in the quarter, down 7.7%.

Hansen further stated, “Our Medical division had a great quarter with double-digit growth in North America and Asia Pacific, we announced the acquisitions of Omnia S.p.A. and Vista Research Group LLC, as well as successfully launched the first phase of our new ERP platform in our US Medical business. On our earnings call, we will discuss revised guidance that will include the acquisition of Omnia and an updated Hemodialysis Water view.”



The following information was filed by Cantel Medical Corp (CMD) on Thursday, February 28, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Cantel Medical Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Cantel Medical Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account